AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Markets Businessinsider

Published November 13, 2026

Americans for Ibogaine Welcomes New Federal Investments in Ibogaine Research and ...

Read the full story at Markets Businessinsider

AUSTIN, TEXAS, November 13th, 2026, FinanceWire. HHS announces new ARPA-H funding for ibogaine development and a $20 million mental health.

Post on X

Share this story

Surfaced by 2 Google Alerts

Ibogaine
Psychedelic press release